Jazz partners with AbCellera on T-cell engager programs for GI cancers in deal valued up to $4.1B, with $56M upfront and up to $792M in milestones per program, plus tiered royalties on net sales spanning mid-single-digit to low double-digit percentages.

on

Sources:

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jazz Pharmaceuticals and AbCellera Forge Up-to-$4 Billion T-Cell ...

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact

Jazz Pharmaceuticals and AbCellera Announce ...

Jazz Pharmaceuticals et AbCellera s’associent sur des anticorps contre le cancer Par Investing.com

Jazz orchestrates a $4bn cancer alliance with AbCellera

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Mul

ABCL and Jazz Pharmaceuticals Enter Collaboration for T-Cell Eng